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ABSTRACT
Purpose: Healthcare-associated infections acquired a high degree of dissemination, being 
considered a serious public health problem and assumed as one of the most common 
adverse events associated with healthcare. They have a significant impact on health systems 
by increasing hospital expenses, and compromising the healthcare quality and effectiveness. 
Surgical site infections (SSI) are considered one of the most serious complications that can 
occur after an orthopaedic surgery. The aim of this study is to contribute to the development 
of a framework to analyse the costs of infections related to hip and knee arthroplasties. 
Methods: A literature review was conducted on databases, and articles published between 
January 2005 and April 2016 were searched.
Findings: A total of 14 articles met the inclusion criteria. Costs were grouped in hospitalization 
and treatment dimensions. For hospitalization, the indicators were the length of stay (LOS) and/
or monetary costs; For treatment, the indicators were number of surgeries and LOS, or monetary 
costs. We observed that LOS is the most commonly used to estimate SSI direct costs. Patients 
who developed hip or knee arthroplasty infections remained in hospital 2.5–3 times longer and 
incurred hospital costs almost three times higher, when compared with an uninfected patient.
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Introduction
Nosocomial infections, currently named by healthcare-
associated infections (HAI), are according to the Euro-
pean Centre of Disease Prevention and Control
(ECDC) and the National Nosocomial Infection Sur-
veillance (NNIS), those arising from adverse reactions
to the presence of an infectious agent or its toxins,
but they were not expressed neither undergoing an
incubation period, at the time of patient’s admission
to the hospital [1,2].
Currently, these have acquired a high degree of dis-
semination, being considered a serious public health
problem. HAIs are assumed as one of the most com-
mon adverse events associated with healthcare and is
estimated that about one in ten hospitalized patients
will acquire an infection after admission. Its high trans-
cendence is due to its high morbidity and mortality,
having become one of the major causes of death in hos-
pitalized patients [3–5]. Also, these have a very signifi-
cant impact on health systems by increasing hospital
expenses and may compromise the healthcare quality
and effectiveness. These extra costs are justified by
the increase of the length of stay (LOS) in about 4–8
days for each infected patient, and the additional diag-
nostics and therapeutic interventions. As a result,
patients who developed HAI remained in hospital 2.5
times longer than uninfected patients and incurred
hospital costs almost three times higher [3,6,7].
Although it is a very current topic, since the begin-
ning of the 1990s several international projects have
been developed in order to improve knowledge about
HAI and at the same time, developed surveillance strat-
egies to promote and guide efforts towards the preven-
tion and control of this kind of infection [8,9]. In this
matter is noteworthy the work done by WHO, CDC,
OECD, and the Council of Europe in the development
of these projects [9], emerged in 1994 in Europe the
first international programme of HAI active surveil-
lance, the Hospitals in Europe Link for Infection Con-
trol through Surveillance (HELICS), that has been
expanding and suffering continuous improvement
since then [10]. Since the creation of HELICS, other
programmes have been developed, such as ‘First
Patient Safety Challenge: Clean Care is Safer Care’
[11] and ‘Second Patient Safety Challenge: Safe Surgery
saves lives’ [12] by the WHO, ‘Prohibit’ [13], and
‘BURDEN’ [14] by the European Union and the
HAI-net [15] by ECDC.
However, the impact of these programmes has not
been as expected. A group of researchers, through a
review article, identified a number of barriers to the
success of these programmes, clustered in three
dimensions: structure, processes, and results [16]. With
regard to structures, they referred to the lack of quality
of hospital infrastructure; lack of human resources,
especially nurses dedicated full-time to HAI prevention
and control programmes; hospital environmental con-
tamination and the organization’s own culture. With
regard to processes, they indicated failures in clinical
processes and management processes, such as poor
infection control practices, wards management, health-
care teams’ management, hospital and cleaning ser-
vices management and the inappropriate use of
resources. With regard to results, all identified barriers
are related with the lack of effective surveillance sys-
tems and the unreliability of epidemiological data [16].
There are four major groups of HAI: ventilator-
associated pneumonia (VAP), catheter-associated
urinary tract infections, surgical site infections (SSI),
and bloodstream infections (CLABSI). In this systema-
tic literature review, our attention turned to the SSI,
focusing on the orthopaedics area, selecting only
those associated with hip or knee arthroplasties.
This work is organized in four major chapters: the
first is a brief introduction to hip and knee arthroplasty
infections; in the second is presented the methodology
used, including database search, data collection, and
analysis; the third chapter is dedicated to results pres-
entation; and in the final chapter are presented the
study’s conclusions.
Hip and knee arthroplasty infections
As the average life expectancy is increasing in industri-
alized countries, the number of patients who need
orthopaedic implant surgery also increases, accentuat-
ing the risk of developing a greater number of infec-
tions [17].
SSI are considered one of the most serious compli-
cations that can occur after arthroplasty [18] and
between 1.5 and 2.5% of all knee and hip arthroplasties
tend to become infected [19]. In agreement with pre-
vious reports, these values can range between 2 and
6% [20].
The LOS is one of the factors that suffers the biggest
changes when the patient gets an infection, and it is the
indicator most commonly used to estimate the direct
costs of SSI [21].
Despite the increase of the hospitalization costs, SSI
also represent a major clinical problem leading to pain-
ful and persistent symptoms in infected patients, need
for new surgical interventions, extra antibiotic treat-
ments, and casual removal or replacement of the pros-
thesis and, in more severe cases to save the patient, a
local amputation is performed [22–24].
The presence of microorganisms on the prosthesis
surface is one of the preconditions for the infection
occurrence. The most often bacteria related with ortho-
paedic implant infections are Staphylococcus aureus and
Staphylococcus epidermidis, particularly the first agent
that is responsible for most of these infections, which
are especially difficult to treat when caused byMethicil-
lin-resistant Staphylococcus aureus (MRSA) [20,25].
There is evidence that, for example, if the screening
and the decolonization of Staphylococcus aureus in hip
or knee replacement surgeries was carried out, about
seven times the costs of the prevention programme
implementation could be avoided [26]. According to
Slover et al. [27] the cost of SSI associated with these
procedures is so great that the cost of a screening pro-
gramme would be recovered by only a small decrease in
infection rate. Reducing the infections will decrease
hospitalization time and increase the availability of
beds for more days. With this, patients would enter
and leave the hospital at a faster rate, reducing the aver-
age cost per patient treated [26].
It is also crucial to develop methods for the early
detection of arthroplasty’s infection, based on symp-
toms such as fever, pain, and tumefaction. If early detec-
tion was achieved, the infection could be treated by
debridement and implant retention. In this way, costs
would be significantly reduced, shortening the recovery
period, and avoiding the costly two-stage revisions [18].
Hereupon, every effort is justified in order to prevent
infection such as strict epidemiological surveillance
and prevention programmes to avoid factors that may
contribute to the onset of infection and, above all, best
clinical practices of all staff involved in surgery [28].
In view of the increased costs related with these
infections, the aim of this study is to perform a sys-
tematic review about the infection costs of hip and
knee arthroplasties in several countries around the
world, in order to better understand their economic
impact.
Methodology
The systematic literature review was done according to
the PRISMA guidelines [29].
Database search
Research was carried out in April 2016 using B-ON,
PubMed, and Science Direct databases in order to
find articles related with hip or knee arthroplasty infec-
tion costs, published between January 2005 and April
2016. To carry out this research, a combination of
terms (Table 1) and an inclusion criterion (publication
period) were applied. In each database, searches were
performed separately for hip and knee arthroplasties.
After carrying out both searches within each one of
these databases, the articles that are repeated were
excluded.
As a result of this research method, 37 articles were
identified from PubMed, 38 from B-ON, and 29 from
Science Direct.
To the articles obtained from this initial research
method, more inclusion and exclusion criteria were
applied (Table 2). In order to keep only one copy of
each article, we exclude the repetition of the same
article in different databases. A final number of 31
articles were obtained: PubMed [17], B-ON [4], and
Science Direct [10].
After verification and further evaluation of the 31
articles, only 16 fulfilled every criteria of inclusion:
PubMed [10], B-ON [1], and Science Direct [5], as
shown in Figure 1.
Data collection and analysis
After the analysis of each article, the following data
were extracted in an excel file: article name, publication
year, country, setting (hospitals, teaching hospitals, ter-
tiary care centre), study methodology, keywords, sum-
mary, and topics (key points).
Results
Through the literature review performed, we identified
a number of key issues responsible for the increased
hospitalization costs, as well as the costs of some treat-
ments and prevention methods for hip or knee arthro-
plasty infections, which can reduce costs and patient
suffering.
Costs for hospitalization and infection
treatment
In Table 3 are presented the results of different studies
in several countries, divided into two major dimen-
sions: hospitalization and treatment. With regard to
hospitalization, the charges will be presented in LOS
and/or monetary costs. With regard to treatment, the
charges will be presented in number of surgeries and
LOS, or monetary costs.
Infection prevention and control
In Table 4 are presented the results of a study con-
ducted in Australia. The researchers evaluated the
cost-effectiveness of implemented strategies claiming
to reduce the risk of deep SSI in hip arthroplasties.
Discussion
Through the literature review performed, we identified
themain costs caused byHAI in hip and knee arthroplas-
ties and the costs of some treatments and prevention
methods for these situations. In agreement with the cur-
rent state of the art, this review identified LOS as the indi-
cator most commonly used to estimate the direct costs of
SSIs, and according to some authors, this happens
because, in addition to the direct relationship between
the LOS and the risk of HAI, the extension of hospitaliz-
ation days is an easily understood measure either by
physicians or by hospital managers, which translates in
the consumption of health resources to treat a compli-
cation [21,35,43]. According to Plowman [6], patients
who developed HAI remained in hospital 2.5 times
longer and incurred hospital costs almost three times
higher, when compared with an uninfected patient who
underwent the same surgical procedure. According to
the articles reviewed, and with regard to LOS and
HAI’s treatment costs, the results were very similar to
those found in the literature related with HAI issues.
Table 1. MeSH and terms related.
Cross infection
HAI
Hospital infection
SSI
Hip arthroplasty
Knee arthroplasty
Hip replacement
Knee replacement
Cost
Table 2. Inclusion and exclusion criteria.
Inclusion criteria
. Publication year: January 2005 to
April 2016;
. Language: English, Portuguese,
and Spanish;
. Contain abstract;
. Only apply to hospitals with
Orthopaedic services/department;
. Be published and available in a
journal in public domain;
. Discuss about costs for hip or
knee arthroplasty;
. Discuss about costs for infections
treatment applied to hip or knee
arthroplasty;
. Discuss about cost-effectiveness
of strategies claiming to reduce
the risk of hip or knee arthroplasty
infections.
Exclusion criteria
. Articles not related with hip or
knee arthroplasty infections;
. Articles with description of
methods, models, and theories
without empirical data;
. Other healthcare entities that
are not hospitals.
Figure 1. Search strategy.
Table 3. Costs for hospitalization and infection treatment.
Costs
Dim Authors Study description Arthroplasty without HAI Arthroplasty with HAI
Hospitalization Jodra et al.
[21]
Study conducted in Madrid, between January
2000 and June 2004. Additional cost for
infection treatment based on excess LOS
attributable to hip arthroplasty infections was
estimated.
Hip:
Average LOS: 17 days
The mean cost per day for a
patient admitted to the
orthopaedic unit: 437.44 €.
Hip:
Average LOS: 53 days
Additional cost per patient who
develops SSI : 14,216.80 €
Irribaren et al.
[28]
Comparative case–control study carried out in
Chile, between January 2000 and December
2004 about excessive direct costs attributed to
hip arthroplasty infections.
Hip:
Average LOS: 13 days
Average cost: $2354
Hip:
Average LOS: 54 days
Average cost: $6174,8 (additional
cost : $3820,1)
Coello et al.
[30]
Study conducted in England, based on
surveillance data of SSI from 140 English
hospitals, included in NINSS (National
Nosocomial Infection Surveillance Service),
between October 1997 and June 2001.
Hip:
Average LOS: 11.1 days
Knee:
Average LOS: 10.3 days
Hip:
Average LOS: 22.6 days
Additional cost: $3342
Knee:
Average LOS: 21.2 days
Additional cost : $3168
Alp et al. [31] Study conducted in Turkey, between April 2011
and April 2013, to evaluate the incidence and
economic burden of prosthetic joint infections.
Hip and Knee:
Average LOS: 7 days
Average cost: $5937
Hip and Knee:
Average LOS: 49 days
Average cost: $16999
Poultsides
et al. [32]
Study conducted in USA to analyse the
hospitalization data from the National Inpatient
Sample (NIS) for hip and knee arthroplasties
between 1998 and 2007.
Hip:
Average LOS: 4.2 days
Average cost: $14,286
Knee:
Average LOS: 4 days
Average cost: $1,334
Hip:
Average LOS: 13.4 days
Average cost: $31432
Knee:
Average LOS: 9.7 days
Average cost: $24 458
Kurtz et al.
[33]
Study conducted in USA, based on NIS to identify
the primary and revision arthroplasty
performed between January 2001 and
December 2009 and to predict the economic
impact of periprosthetic joint infection on the
US health system.
– Hip:
Average of cost and LOS:
2001: $31 300; 11.5 days
2009: $30 300; 9.5 days
Knee:
Average of cost and LOS:
2001: $25 300; 9.3 days
2009: $24 200; 7.2 days
Kapadia et al.
[34]
Study with a group control conducted in USA,
between January 2007 and December 2011.
The impact of periprosthetic joint infections on
the LOS, readmissions and associated costs
measured.
Knee:
Average LOS: 3 days
Days in hospital (mean): 3.4
days
Readmissions (mean): 0.14
Average cost: $28 249.57
Knee:
Average LOS: 5.3 days
Days in hospital (mean): 23.7 days
Readmissions (mean): 3.43
Average cost: $116 382. 65
Dal-Paz et al.
[35]
Study conducted between 2006 and 2007 in
Brazil to estimate the direct costs of the 34
patients’ treatment who acquired knee
arthroplasty infections, by analyzing medical
records.
– Knee:
Average LOS: 29,7 days
Additional Average |Cost: $2,701.29
Garrido-
Gómez et al.
[18]
Retrospective study conducted between January
2005 and January 2010 in Spain, with 79
patients who were diagnosed and treated for
knee arthroplasty infection.
– Knee:
Average Cost: 40 542 €.
Klouche et al.
[36]
Retrospective study conducted in France
between January and December 2006, to
determine the cost of revision of infected hip
arthroplasty and to compare these costs to
those of primary and revision of non-infected
hip arthroplasty.
Hip:
Average cost of primary
arthroplasty: 9028€
Average cost of aseptic
revision : 12 409 €
Hip:
Average Cost of septic revision: 32
546€
Peel et al. [37] Study conducted at St. Vincent’s Hospital
Melbourne, between January 2011 and June
2012, to evaluate the direct hospital costs in the
first 30-day follow-up of patients undergoing
total hip and knee arthroplasties (data were
extrapolated for Australian population).
– Hip and Knee:
SSI raise the arthroplasty’s cost
around 76% in the hip, and around
54% in the knee.
The estimated average cost in the
first 30 days following surgery to
Australian population: $97.2 million
AU
González-
Vélez et al.
[38]
A matched case–control study conducted at
Ramon y Cajal University Hospital in Spain
between 1 January 2005 and 31 December
2011. The researchers estimated the excess
direct costs of hip arthroplasty
Hip:
Average LOS: 21 days
Average Cost : 10 828 €
Hip:
Average LOS: 58 days
Average Cost :25 288 €
Gow et al. [39] Retrospective case–control study conducted at
Auckland City Hospital (New Zealand) to
determine the excess costs attributable to hip
and knee arthroplasty infections.
– Hip and Knee:
Excess Average LOS: 42 days
Excess Average Cost: $40,121
(Continued )
It can also be concluded that comparing the LOS and
treatment costs between hip arthroplasty infection and
knee arthroplasty infection, the first were, in general,
higher. Also, and being more specific, patients who
developed deep incisional and organ/space SSI, in case
of hip or knee arthroplasties, remained in hospital two
times longer than those with superficial SSI [21,30].
In addition to the LOS average cost, some articles
reviewed were even more specific, discriminating the
antimicrobial costs, readmission’s number, laboratory
tests and even the influence of age, gender, and race
in HAI’s treatment costs. According to Iribarren et al.
[28], in cases of arthroplasty infection, only the antimi-
crobial’s additional costs was about $2421 per patient
treated. According to Dal-Paz et al. [35], the additional
costs in antibiotic therapy and laboratory tests to treat
infections of a knee replacement, were approximately
$600 per patient.
Besides the extension of the LOS, the readmission’s
number also undergo a considerable change. Kapadia
et al. [34], in his study about knee arthroplasty infec-
tions, concluded that the readmission’s rate increased
about four times in infected patients.
Besides the costs previously referenced, another
USA-based study went further and concluded that
there are other factors related to the patient and with
its geographical location, even within the same country,
whichwill affect theHAI’s treatment costs [33]: Patients
from different geographic locations generate different
costs, e.g. patients living in the South or the Midwest
had a lower cost ($4000–$5000) than those in the
West or the Northeast. The patient’s race also has an
influence on costs, e.g. Asian and African-American
patients generated, on average, an additional expense
of $4700 and $1700, respectively, when compared
with caucasian patients. Another important issues are
age and gender, e.g. at a given age level, female patients
incurred a higher HAI’s treatment cost than male
patients, with particular emphasis in the ranges between
the ages 45 and 54 years and the ages 75 and 79 years.
Treatment
Regarding HAI’s treatment method, as mentioned pre-
viously, the state of art reveals that if early detection
was achieved, the infection could be treated by debride-
ment and implant retention [18]. According to Merol-
lini et al. [40] study, four HAIs treatment methods were
applied. They concluded that the treatment with debri-
dement, antibiotics, and implant retention, had an
average cost around $19,688 AU and a two-stage revi-
sion had an average cost of $ 44,744 AU, which is more
than double than the first one. The importance of pri-
mary prevention should not be ignored, because the
occurrence of SSI might be reduced by introducing
more cost-effective infection prevention measures.
According to Moojen et al. [41], we should aim
treatment strategies that are both efficient and cost-
effective. They concluded that the strategy of a single
debridement appears to be at least as successful for
retention of the primary implant and control of infec-
tion as a strategy with multiple surgical debridements,
without compromising the clinical effectiveness. How-
ever, considering equal clinical results, the first one will
reduce the costs of multiple surgeries (2 less surgeries),
hospitalizations (2 times lower), and revision implants.
The single debridement will also reduce the morbidity
and psychological discomfort of the patient.
Table 3. Continued.
Costs
Dim Authors Study description Arthroplasty without HAI Arthroplasty with HAI
Treatment Merollini et al.
[40]
Study conducted in Australia, with patients
undergoing primary hip arthroplasty and
treatment for infection between January 2006
and December 2009. Different treatments costs
were identified from 114 patients with deep
hip arthroplasty infection.
– Hip:
Debridement, antibiotics and implant
retention:
Average cost per patient: $19 688
AU
1-stage revision:
Average cost per patient: $26 722
AU
2-stage revision:
Average cost per patient: $44 744
AU
excision of arthroplasty:
Average cost per patient: $23 805
AU
Moojen et al.
[41]
Retrospective study of a prospective database
conducted in two large teaching hospitals in
Holland, between 2001 and 2008. Data from 68
patients treated to a deep postoperative
infection of a total hip arthroplasty were
obtained. One of the hospitals used a single
surgical debridement to treat the infection, the
other used a system with multiple surgical
debridement.
– Hip:
Single surgical debridement:
Average number of surgeries: 1
Average length of antibiotic
treatment: 13 weeks;
Average LOS: 29 days.
Multiple surgical debridement:
Average number of surgeries: 3
Average length of antibiotic
treatment: 23 weeks;
Average LOS: 59 days
Prevention
Regarding infection prevention and control methods,
several studies show resources or costs that may be
saved through effective prevention programmes. How-
ever, authors do not provide information about the cost
of infection prevention efforts or number and quality-
of-life years gained through those investments [26].
If costs are reduced by the implemented changes,
there is no need to show the health benefits in terms
of years of life gained or quality-adjusted life years
gained. However, in cases where the cost savings do
not compensate the increase of total costs, the health
outcomes need to be demonstrated [26].
According to Merollini, Crawford et al. [42], scarce
resources should be used efficiently and for this, it is
important to establish a cost-effective approach to pre-
venting SSI in the total hip arthroplasty. The preven-
tion of these infections can not only be centred in
costs reduction but also in patient’s suffering reduction.
The additional use of antibiotic-impregnated (AP+
ABC), compared with only antibiotic prophylaxis
(AP), would prevent 46 deep SSI and save $3,909 for
each QALY gained, leading to cost savings. Using anti-
biotic cement in addition to antibiotic prophylaxis (AP
+ ABC) would generate an extra 32 QALYs while sav-
ing over AUD $123,000. Not using AP would increase
costs by approximately $1.5 million with a 163 QALYs
lost. Using laminar air operating rooms (AP+ LOR)
would increase costs by approximately $4.6 million,
and 127 QALYs are lost. If all hospitals adopted the
antibiotic-impregnated cement strategy (AP+ ABC),
besides improving health outcomes among hospital-
ized patients and save lives, they could save many
resources that could be used in other areas in need.
Conclusion
Quantifying the exact economic impact of HAI is an
ongoing international challenge and the use of the
direct hospitalization costs has been suggested as the
best method to estimate the direct HAI’s costs. These
represent the real costs to the hospital for the items
and services used by each patient and have a direct
impact on hospital budget.
This study has some limitations, mainly related with
the difficulties to obtain articles related with HAI cost
analysis from databases, and limited access to cost
information (e.g. no cost discrimination).
In the majority of the articles reviewed in this study,
the cost analyses of HAI, more specifically about hip
and knee arthroplasties infections, focus primarily on
direct hospitalization costs. The LOS was the most
commonly used indicator to estimate the direct costs
of these SSIs in the reviewed articles. By using this indi-
cator, evidence suggests that patients who developed
HAI remained in hospital 2.5–3 times longer and
incurred hospital costs almost three times higher,
when compared with an uninfected patient who under-
went the same surgical procedures. However, this indi-
cator is restricted to the direct medical costs, and does
not include information with regard to the real cost to
patients and society in lost earnings (indirect costs).
The measurement of indirect cost is indeed a funda-
mental healthcare management challenge as there is
high degree of difficult to account for exact cost and,
generally, these are assumed to be much higher than
direct costs. Thus, evidence gathered in this article
allows us to argue that the cost analysis of HAI per-
formed in international studies has been continuously
underestimating real economic impacts of HAI in hip
and knee arthroplasties. This key idea can no longer
be ignored by healthcare managers and decision
makers and further research must be done to explore
better these issues.
Table 4. Cost of strategies to prevent infection.
Authors Study description Strategies Costs QALY* Savings per QALY*
Merollini
et al. [42]
At this study, the researchers simulated long-
term health and cost outcomes of a
hypothetical cohort of 30,000 patients
undergoing total hip arthroplasty.
Baseline use of AP was compared with no AP,
antibiotic-impregnated cement (AP + ABC),
and laminar air operating rooms (AP + LOR).
AP vs. no
AP
No AP would
increase costs by
about $1.5 million
AU
No AP would lose
163 QALYs.
–
AP vs. (AP
+ ABC)
(AP + ABC) would
save about $126
000 AU
(AP + ABC) would
generate an
extra 32 QALYs
The use of (AP + ABC) would
prevent 46 deep infections
and would save $3,909 AU
per QALY gained
AP vs. (AP
+ LOR)
(AP + LOR) would
increase costs by
about $4.6 million
AU
(AP + LOR) would
lose 127 QALYs.
–
*QALY – quality-adjusted life years.
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